HOME >> BIOLOGY >> NEWS
Could estriol be the elixir for MS?

It has long been common knowledge that pregnant women with multiple sclerosis (MS) experience a sharp drop in the disease's symptoms during the course of their pregnancy.

Some years back, Dr. Rhonda Voskuhl, director of UCLA's Multiple Sclerosis Program, and her colleagues discovered the cause. They found that a female sex hormone called estriol, which is produced during pregnancy, was responsible for the suppression. Four years ago, Voskuhl followed that discovery with a pilot study in which 10 non-pregnant women with MS were given estriol, yielding what she described as "pretty remarkable" results an 80 percent drop in inflammatory lesions in the brain, a hallmark of the disease.

This month, Voskuhl begins a much larger trial of estriol, one that will involve 150 patients at multiple locations over the next two years. The prospects, she said, are exciting.

Multiple sclerosis is an autoimmune disease of the central nervous system that attacks the tissue surrounding the brain's nerve fibers. This tissue, called myelin, can be thought of as the insulation wrapped around an electrical wire. When the myelin is damaged, the nerve's ability to send signals to and from the brain is interfered with, resulting in symptoms common to MS, including problems with balance, memory, vision loss and more.

Currently, anti-inflammatory drugs used to treat MS lessen the symptoms and slow the progression of the disease. But they must be given by injection daily, weekly or monthly depending on the drug and are expensive, costing between $12,000 to $24,000 a year.

Estriol is a hormone produced by the placenta that is virtually undetectable until pregnancy, when it progressively increases. It is thought that its role is to suppress a woman's immune system when she is pregnant, so that the fetus will not be seen by the body as a foreign "invader."

"The beauty of estriol is that it can be given as a pill, not a shot, and
'"/>

Contact: Mark Wheeler
mwheeler@mednet.ucla.edu
310-794-2265
University of California - Los Angeles
22-Mar-2007


Page: 1 2

Related biology news :

1. Could fungal collection hold the key to new life-saving drugs?
2. Could USA presidential DNA trail reveal Middle-Eastern origins?
3. Quantum dots reviewed -- Could these nanoparticles hold the cure to cancer?
4. Could a pint of cider help keep the doctor away?
5. Friend or foe: Could a protein linked to Alzheimers be related to vision loss in seniors?
6. Could plain soap and probiotics beat hospital bugs?
7. Could better mangrove habitats have spared lives in the 2004 tsunami?
8. Recurrent miscarriages: Could prednisolone reduce the occurrence of this distressing condition?
9. Could microbes solve Russias chemical weapons conundrum?
10. Could schizophrenia arise from a single defect?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/14/2019)... ... January 14, 2019 , ... CellMax ... cancer cells in blood, will present new findings at the ASCO Gastrointestinal Cancer ... colorectal cancer. The results from this study show CellMax Life’s blood test, based ...
(Date:1/10/2019)... (PRWEB) , ... January 09, 2019 , ... Dr. Beanlands ... Heart Institute in Ottawa, Ontario, Canada. He is also Director of its National ... of Medicine, in the Department of Radiology, and in the Department of Cellular and ...
(Date:1/10/2019)... ... 2019 , ... A major goal for pharmaceutical companies has ... significantly more expensive in vivo studies in order to reduce costs and improve ... researchers have begun to adopt 3D cell culture models which have been shown ...
Breaking Biology News(10 mins):
(Date:12/20/2018)... ... December 20, 2018 , ... New Year’s brings reflection ... changes in regulations in the European Union (EU) on the horizon, Jim Kasic, president ... , “The transition to the EU Medical Device Regulation (MDR), digital health, and big ...
(Date:12/18/2018)... ... December 18, 2018 , ... Patients with early stages of breast cancer who ... post-treatment versus whole breast irradiation, a new study suggests. , Patients with early stage ... irradiation after removal of the cancerous tumor because there is a 30 to 40 ...
(Date:12/13/2018)... ... December 13, 2018 , ... Microbial Discovery Group LLC (MDG) ... been part of their strategic plan and an important milestone in increasing their ... opportunities for MDG within the $44 Billion human probiotic market. This plan is ...
(Date:12/5/2018)... (PRWEB) , ... December 04, ... ... an established North American full-service contract research organization (CRO), announced the acquisition ... transaction significantly strengthens ARG’s reach and experience in the management of clinical ...
Breaking Biology Technology:
Cached News: